Selank vs SSRIs: How They Differ

Selank is a seven-amino-acid peptide built on tuftsin and studied in anxiety disorders, while SSRIs (selective serotonin reuptake inhibitors) are a class of approved antidepressant medicines that block the serotonin transporter and are used for depression and anxiety disorders. The core difference is the target: SSRIs act on serotonin reuptake, while Selank’s research points to enkephalin-degrading enzymes and allosteric modulation of GABA binding. Their evidence also differs in scale, from hundreds of SSRI trials to a small set of Selank clinical studies. Here is how they compare.

Findings

• SSRIs inhibit presynaptic reuptake of serotonin at the serotonin transporter, raising serotonin at the synapse; six structurally unrelated SSRIs share that mechanism (2021).
• A network meta-analysis of 522 trials and 116,477 adults with major depression found every one of 21 antidepressants more effective than placebo (2018).
• For generalised anxiety disorder, a network meta-analysis of 89 trials and 25,441 patients found escitalopram, sertraline and fluoxetine efficacious against placebo (2019).
• Selank’s anti-anxiety effect matched the benzodiazepine medazepam’s in 62 patients with generalised anxiety disorder or neurasthenia, with added anti-fatigue and stimulant effects (2008).
• In a 2014 study of 60 patients, Selank’s anti-anxiety effect lasted a week after the last administration.

What are SSRIs?

SSRIs became a mainstay of psychiatric treatment after fluoxetine was introduced in the United States in 1988. Their primary mechanism is to inhibit presynaptic reuptake of serotonin at the serotonin transporter, which increases serotonin at the postsynaptic membrane. The six major SSRIs marketed in the United States are fluoxetine, citalopram, escitalopram, paroxetine, sertraline (Zoloft) and fluvoxamine: structurally unrelated molecules with a shared mechanism, but each with its own pharmacokinetics and side-effect profile (Edinoff et al., Neurol Int, 2021).

SSRIs act on the transporter directly, yet the clinical effect of most antidepressants arrives with a delay. That gap is one reason researchers look beyond a purely neurotransmitter-based explanation, toward early changes in emotional and social processing and toward neural plasticity (Harmer et al., Lancet Psychiatry, 2017).

The human evidence for SSRIs

The largest synthesis in depression pooled 522 double-blind randomised trials covering 116,477 participants and 21 antidepressants, SSRIs among them. All 21 were more efficacious than placebo. In head-to-head trials, escitalopram and paroxetine were among the more effective drugs, and citalopram, escitalopram, fluoxetine and sertraline among the better tolerated (Cipriani et al., Lancet, 2018).

In generalised anxiety disorder, a network meta-analysis of 89 trials and 25,441 patients ranked escitalopram among the drugs more efficacious than placebo with relatively good acceptability. Sertraline and fluoxetine were also efficacious and well tolerated, though with smaller samples, and paroxetine was effective but less well tolerated (Slee et al., Lancet, 2019). The class carries a boxed warning on suicidality in children and young adults aged 18 to 24 (Edinoff et al., 2021).

What is Selank?

Selank is the synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed from tuftsin, a peptide the body makes (Kolik et al., Bull Exp Biol Med, 2019). Its anti-anxiety mechanism research centres on two systems. It inhibited the enzymes that break down enkephalins in human plasma, and enkephalin half-life was shortened in patients with generalised anxiety (Zozulya et al., Bull Exp Biol Med, 2001). In radioligand work it acted as a positive allosteric modulator of GABA binding (Vyunova et al., Protein Pept Lett, 2018). It is introduced in more depth in Selank peptide: what the research covers.

Selank and serotonin

Selank’s effect on serotonin looks nothing like an SSRI’s. In a 2008 mouse study, it raised noradrenaline in the hypothalamus of two strains and, in the more anxious BALB/c strain, lowered serotonin and its metabolite 5-HIAA in the hippocampus, leaving them unchanged in the other strain; the authors read this as a sign of selective anxiolytic action (Narkevich et al., Eksp Klin Farmakol, 2008). In rats, Selank changed the expression of 45 neurotransmission genes within an hour, a panel that included serotonin and dopamine receptors (Volkova et al., Front Pharmacol, 2016). Rat work has also linked it to BDNF, a growth factor tied to neural plasticity, in the hippocampus and prefrontal cortex (Kolik et al., 2019).

The human studies of Selank

Selank’s clinical studies are in anxiety disorders, with benzodiazepines as comparators. In 2008, 62 patients with generalised anxiety disorder or neurasthenia received Selank (30) or medazepam (32); the anti-anxiety effects were similar, Selank added antiasthenic and psychostimulant effects, and serum enkephalin half-life rose during the Selank course (Zozulia et al., Zh Nevrol Psikhiatr Im S S Korsakova, 2008). In 2014, a study of 60 patients with anxiety-phobic and somatoform disorders reported a pronounced anti-anxiety effect lasting a week after the last administration, a mild nootropic effect and better quality of life (Medvedev et al., 2014). In 2015, adding Selank to phenazepam brought improvement sooner and reduced the benzodiazepine’s side effects (Medvedev et al., 2015). The full record is in Selank and anxiety: the research.

How do Selank and SSRIs compare side by side?

Question	Selank	SSRIs
What is it?	Synthetic tuftsin-based peptide	Class of small-molecule antidepressants
Size	Seven amino acids	Small molecules, not peptides
Mechanism focus	Enkephalin-degrading enzymes; allosteric GABA modulation	Serotonin transporter blockade
Effect on serotonin in research	Lowered hippocampal serotonin in one anxious mouse strain	Raises synaptic serotonin
Main research area	Generalised anxiety, neurasthenia, anxiety-phobic disorders	Depression and anxiety disorders
Human evidence	Russian clinical studies, 2008 to 2015	Hundreds of randomised trials
Status	Research compound	Approved prescription medicines
Forms we supply	Lyophilised vial and nasal spray	Not supplied

Where the two research literatures meet and part

• Condition studied: both have anxiety research, but SSRIs carry the depression evidence. We found no published controlled trial of Selank in major depressive disorder.
• Comparators: Selank was compared with benzodiazepines, not with SSRIs. We found no head-to-head trial between Selank and any SSRI.
• Time course: SSRI research deals with a delayed clinical onset; Selank’s 2014 study tracked an effect that persisted for a week after the course ended, a different kind of timing question.
• Systems: SSRI research is anchored in serotonin; Selank’s in enkephalins and GABA, with serotonin changes reported only in animal work.

For Selank against a benzodiazepine, see Selank vs Xanax; for its sister peptide, Semax vs Selank.

How is Selank supplied?

We supply Selank as a 10 mg lyophilised vial, as the ready-mixed Selank Nasal Spray (a metered pump delivering 0.175 mL per press) and in the Sleep & Calm Spray Stack with DSIP. Vials are reconstituted with bacteriostatic water; the Selank reconstitution guide has a calculator, and How long does Selank last? covers storage. Certificates of analysis are on the lab reports page, and every order ships from within Canada by Canada Post Xpresspost.

Frequently asked questions

What is the difference between Selank and an SSRI?

SSRIs are approved antidepressants that block the serotonin transporter and raise synaptic serotonin. Selank is a seven-amino-acid tuftsin-based peptide whose research points to enkephalin-degrading enzymes and allosteric modulation of GABA binding rather than serotonin reuptake.

Does Selank affect serotonin?

In a 2008 mouse study, Selank lowered serotonin and its metabolite in the hippocampus of the more anxious BALB/c strain and did not change them in another strain. That is a different pattern from an SSRI, which raises synaptic serotonin.

Has Selank been compared with SSRIs?

We found no published head-to-head trial. Selank’s clinical comparators were the benzodiazepines medazepam and phenazepam, and its studies were in anxiety disorders rather than major depression.

Has Selank been studied for depression?

Its human studies were in generalised anxiety disorder, neurasthenia and anxiety-phobic and somatoform disorders. We found no published controlled trial of Selank in major depressive disorder.

Where can I buy Selank in Canada?

Vistara Labs supplies Selank as a 10 mg lyophilised vial and a ready-mixed nasal spray, shipped from within Canada by Canada Post Xpresspost. See Buy Selank Nasal Spray in Canada for the spray.

Product details from vistaralabs.ca, October 2026. Sources: Edinoff AN et al. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021. PMID 34449705. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017. PMID 28153641. Cipriani A et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018. PMID 29477251. Slee A et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019. PMID 30712879. Kolik LG et al. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats. Bull Exp Biol Med. 2019. PMID 31625062. Zozulya AA et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001. PMID 11550013. Vyunova TV et al. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein Pept Lett. 2018. PMID 30255741. Narkevich VB et al. Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study. Eksp Klin Farmakol. 2008. PMID 19093364. Volkova A et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016. PMID 26924987. Zozulia AA et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID 18454096. Medvedev VE et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PMID 25176261. Medvedev VE et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PMID 26356395.

More on this: Peptides for Focus and Anxiety: What the Research Shows.